BD&L strategy for oncology leadership

Less than 1 min read

Resource, Commercial, Portfolio, Licensing & Development

Scroll

Over the last decade, oncology revenue growth for top pharma players has largely been driven by BD&L. Our experts take a deep dive into the growing oncology market uncovering the top drivers and activities of revenue growth.

Explore the full analysis, takeaways, and strategic recommendations for how to engage in BD&L to drive growth in oncology.

Read the full analysis

Contact us.

To speak with our experts, fill out the form below.

Insights

More insights.

See all insights

Clement Francois

Navigating the Joint Clinical Assessment (JCA) with a strategic market access partner

Navigate the JCA launch with Putnam's expert strategies. Unlock optimal market access with PICO-driven insights, evidence plans & regulatory synergy.

Key outcomes of ASCO24

Our experts shared key themes for #ASCO24 and now summarize the vital insights on antibody drug conjugates, radiopharmaceuticals, and bispecifics.

The expanding concept of value – Implications for manufacturers and payers

Micro-tutorial on payer value drivers, tackling challenges in their integration into payer/HTA frameworks and generating robust supporting evidence.

Centers of Excellence

AI at Putnam

Open roles